|
1
|
Friedenreich CM: Physical activity and
breast cancer: Review of the epidemiologic evidence and biologic
mechanisms. Recent Results Cancer Res. 188:125–139. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng L, Zhou B, Meng X, Zhu W, Zuo A,
Wang X, Jiang R and Yu S: A model of spontaneous mouse mammary
tumor for human estrogen receptor- and progesterone
receptor-negative breast cancer. Int J Oncol. 45:2241–2249.
2014.PubMed/NCBI
|
|
3
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dirsch VM, Kiemer AK, Wagner H and Vollmar
AM: The triterpenoid quinonemethide pristimerin inhibits induction
of inducible nitric oxide synthase in murine macrophages. Eur J
Pharmacol. 336:211–217. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Deeb D, Gao X, Liu YB, Pindolia K and
Gautam SC: Pristimerin, a quinonemethide triterpenoid, induces
apoptosis in pancreatic cancer cells through the inhibition of
pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic
Bcl-2. Int J Oncol. 44:1707–1715. 2014.PubMed/NCBI
|
|
7
|
Yan YY, Bai JP, Xie Y, Yu JZ and Ma CG:
The triterpenoid pristimerin induces U87 glioma cell apoptosis
through reactive oxygen species-mediated mitochondrial dysfunction.
Oncol Lett. 5:242–248. 2013.PubMed/NCBI
|
|
8
|
Tiedemann RE, Schmidt J, Keats JJ, Shi CX,
Zhu YX, Palmer SE, Mao X, Schimmer AD and Stewart AK:
Identification of a potent natural triterpenoid inhibitor of
proteosome chymotrypsin-like activity and NF-kappaB with
antimyeloma activity in vitro and in vivo. Blood. 113:4027–4037.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Byun JY, Kim MJ, Eum DY, Yoon CH, Seo WD,
Park KH, Hyun JW, Lee YS, Lee JS, Yoon MY and Lee SJ: Reactive
oxygen species-dependent activation of Bax and poly(ADP-ribose)
polymerase-1 is required for mitochondrial cell death induced by
triterpenoid pristimerin in human cervical cancer cells. Mol
Pharmacol. 76:734–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu YB, Gao X, Deeb D, Brigolin C, Zhang
Y, Shaw J, Pindolia K and Gautam SC: Ubiquitin-proteasomal
degradation of antiapoptotic survivin facilitates induction of
apoptosis in prostate cancer cells by pristimerin. Int J Oncol.
45:1735–1741. 2014.PubMed/NCBI
|
|
11
|
Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR
and Wu YC: Pristimerin induces caspase-dependent apoptosis in
MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer
Ther. 4:1277–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mu XM, Shi W, Sun LX, Li H, Wang YR, Jiang
ZZ and Zhang LY: Pristimerin inhibits breast cancer cell migration
by up- regulating regulator of G protein signaling 4 expression.
Asian Pac J Cancer Prev. 13:1097–1104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie G, Zhu X, Li Q, Gu M, He Z, Wu J, Li
J, Lin Y, Li M, She Z and Yuan J: SZ-685C, a marine anthraquinone,
is a potent inducer of apoptosis with anticancer activity by
suppression of the Akt/FOXO pathway. Br J Pharmacol. 159:689–697.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bliss CI: The calculation of the
dose-mortality curve. Ann Appl Biol. 22:134–167. 1935. View Article : Google Scholar
|
|
15
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Datta SR, Dudek H, Tao X, Masters S, Fu H,
Gotoh Y and Greenberg ME: Akt phosphorylation of BAD couples
survival signals to the cell-intrinsic death machinery. Cell.
91:231–241. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Setzer WN and Setzer MC: Plant-derived
triterpenoids as potential antineoplastic agents. Mini Rev Med
Chem. 3:540–556. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Petronelli A, Pannitteri G and Testa U:
Triterpenoids as new promising anticancer drugs. Anticancer Drugs.
20:880–892. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
|
20
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raguz S and Yagüe E: Resistance to
chemotherapy: New treatments and novel insights into an old
problem. Br J Cancer. 99:387–391. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kashkar H: X-linked inhibitor of
apoptosis: A chemoresistance factor or a hollow promise. Clin
Cancer Res. 16:4496–4502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Katso R, Okkenhaug K, Ahmadi K, White S,
Timms J and Waterfield MD: Cellular function of phosphoinositide
3-kinases: Implications for development, homeostasis and cancer.
Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sui T, Ma L, Bai X, Li Q and Xu X:
Resveratrol inhibits the phosphatidylinositide 3-kinase/protein
kinase B/mammalian target of rapamycin signaling pathway in the
human chronic myeloid leukemia K562 cell line. Oncol Lett.
7:2093–2098. 2014.PubMed/NCBI
|
|
25
|
Knight ZA and Shokat KM: Chemically
targeting the PI3K family. Biochem Soc Trans. 35:245–249. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao X, Liu Y, Deeb D, Arbab AS and Gautam
SC: Anticancer activity of pristimerin in ovarian carcinoma cells
is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR
signaling. J Exp Ther Oncol. 10:275–283. 2014.PubMed/NCBI
|
|
27
|
Marchion DC, Cottrill HM, Xiong Y, Chen N,
Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, et
al: BAD phosphorylation determines ovarian cancer chemosensitivity
and patient survival. Clin Cancer Res. 17:6356–6366. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Q, Yogosawa S, Iizumi Y, Sakai T and
Sowa Y: The alkaloid emetine sensitizes ovarian carcinoma cells to
cisplatin through downregulation of bcl-xL. Int J Oncol.
46:389–394. 2015.PubMed/NCBI
|
|
29
|
Villedieu M, Louis MH, Dutoit S, Brotin E,
Lincet H, Duigou F, Staedel C, Gauduchon P and Poulain L: Absence
of Bcl-xL down-regulation in response to cisplatin is associated
with chemoresistance in ovarian carcinoma cells. Gynecol Oncol.
105:31–44. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Williams J, Lucas PC, Griffith KA, Choi M,
Fogoros S, Hu YY and Liu JR: Expression of Bcl-xL in ovarian
carcinoma is associated with chemoresistance and recurrent disease.
Gynecol Oncol. 96:287–295. 2005. View Article : Google Scholar : PubMed/NCBI
|
